Literature DB >> 8957065

Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

E Ichimura1, A Maeshima, T Nakajima, T Nakamura.   

Abstract

The expression of c-met/HGF receptor was evaluated in non-small cell lung cancers (NSCLC) by western blot analysis of 11 established cell lines and 104 surgically resected tissues. All cancer cell lines (eight adenocarcinomas, two squamous cell carcinomas and a large cell carcinoma) showed strong c-met protein bands of 145 kDa and 170 kDa. Moreover, c-met protein was demonstrated in 34 (72.3%) of 47 surgically resected adenocarcinomas, 20 (38.5%) of 52 squamous cell carcinomas and 3 of 5 others, and the results were mostly confirmed immunohistochemically in formalin-fixed and paraffin-embedded tumors of the same case. Although squamous cell carcinomas showed relatively high c-met protein expression in established cell lines, more adenocarcinomas than squamous cell carcinomas showed c-met protein expression in the original cancers. Furthermore, two cell lines used in this study originated from primary cancers negative for c-met protein expression, suggesting that c-met protein expression might be influenced by cultivation. Furthermore, clinicopathological study revealed that NSCLC with c-met protein expression tended to be in a higher pathological tumor stage and to have a worse outcome than those without such expression. In conclusion, c-met protein is expressed in cell lines and primary tumors of NSCLC, and this phenomenon is probably closely related to the aggressive behavior or progression of NSCLC, especially of adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957065      PMCID: PMC5920996          DOI: 10.1111/j.1349-7006.1996.tb03111.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

Authors:  M Park; M Dean; K Kaul; M J Braun; M A Gonda; G Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

Authors:  V Rusch; J Baselga; C Cordon-Cardo; J Orazem; M Zaman; S Hoda; J McIntosh; J Kurie; E Dmitrovsky
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

4.  Developmental changes in hepatocyte growth factor mRNA and its receptor in rat liver, kidney and lung.

Authors:  M Kagoshima; T Kinoshita; K Matsumoto; T Nakamura
Journal:  Eur J Biochem       Date:  1992-11-15

5.  myc family gene abnormality in lung cancers and its relation to xenotransplantability.

Authors:  A Gemma; T Nakajima; M Shiraishi; M Noguchi; M Gotoh; T Sekiya; H Niitani; Y Shimosato
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

6.  Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species.

Authors:  H Tajima; K Matsumoto; T Nakamura
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

7.  Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.

Authors:  T Furukawa; W P Duguid; M Kobari; S Matsuno; M S Tsao
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

8.  Hepatocyte growth factor stimulates DNA synthesis in alveolar epithelial type II cells in vitro.

Authors:  M Shiratori; G Michalopoulos; H Shinozuka; G Singh; H Ogasawara; S L Katyal
Journal:  Am J Respir Cell Mol Biol       Date:  1995-02       Impact factor: 6.914

9.  Autocrine stimulation of motility in SBC-5 human lung carcinoma cells by a two-kringle variant of HGF.

Authors:  Y Itakura; T Yamamoto; K Matsumoto; T Nakamura
Journal:  Cancer Lett       Date:  1994-08-15       Impact factor: 8.679

10.  Human lung cancer cell line producing hepatocyte growth factor/scatter factor.

Authors:  Y Yoshinaga; S Fujita; M Gotoh; T Nakamura; M Kikuchi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  67 in total

1.  cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Authors:  Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

Review 2.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

3.  Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Authors:  Ana M Gonzalez-Angulo; Huiqin Chen; Meghan S Karuturi; Mariana Chavez-MacGregor; Spyrus Tsavachidis; Funda Meric-Bernstam; Kim-Anh Do; Gabriel N Hortobagyi; Patricia A Thompson; Gordon B Mills; Melissa L Bondy; George R Blumenschein
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

4.  Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.

Authors:  Roya Navab; Jiang Liu; Isolde Seiden-Long; Warren Shih; Ming Li; Bizhan Bandarchi; Yan Chen; Davina Lau; Yen-Fen Zu; Dave Cescon; Chang Qi Zhu; Shawna Organ; Emin Ibrahimov; Dina Ohanessian; Ming-Sound Tsao
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 5.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

6.  Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.

Authors:  Yuichi Fujimoto; Shinsaku Togo; Miniwan Tulafu; Kazue Shimizu; Takuo Hayashi; Toshimasa Uekusa; Yuichirou Honma; Yukiko Namba; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Kazuhisa Takahashi
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

8.  MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET.

Authors:  Xi Chen; Zhong-Kai Tong; Jian-Ya Zhou; Ya-Ke Yao; Shu-Meng Zhang; Jian-Ying Zhou
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

9.  First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.

Authors:  Vicki L Keedy; Heinz-Josef Lenz; Leonard Saltz; Jennifer G Whisenant; Jordan D Berlin; Luis H Camacho
Journal:  Invest New Drugs       Date:  2018-01-29       Impact factor: 3.850

Review 10.  c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.